Patents Assigned to Rhone-Poulenc Rorer
  • Patent number: 6239270
    Abstract: The present invention relates to the isolation of a cDNA clone encoding the calcium sensor in human placenta and subsequent Northern blots confirming the mRNA expression also in human parathyroid and kidney tubule cells. Close sequence similarity is demonstrated with the rat Heymann nephritis antigen, a glycoprotein of the kidney tubule brush border with calcium binding ability. Immunohistochemistry substantiates a tissue distribution of the calcium sensor protein similar to that previously described for the Heymann antigen. It is proposed that the identified calcium sensor protein constitutes a universal sensor for recognition of variation in extracellular calcium, and that it plays a key role for calcium regulation via different organ systems. The calcium sensor protein belongs to the LDL-superfamily of glycoproteins, claimed to function primarily as protein receptors, but with functionally important calcium binding capacity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 29, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Göran Akerström, Claes Juhlin, Lars Rask, Göran Hjälm, Clarence C. Morse, Edward M. Murray, Gregg R. Crumley
  • Patent number: 6235497
    Abstract: A nucleic sequence coding for a protein involved in the vesicular transport of acetylcholine, the corresponding protein and the promoter sequences implicated in expressing said protein are disclosed. The invention also discloses expression vectors containing said sequence and the therapeutic use of said sequence or said vectors.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: May 22, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Stéphane Bejanin, Sylvie Berrard, Riccardo Cervini, Jacques Mallet
  • Patent number: 6217866
    Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 17, 2001
    Assignee: Rhone-Poulenc Rorer International (Holdings), Inc.
    Inventors: Joseph Schlessinger, David Givol, Francoise Bellot, Richard Kris, George A. Ricca, Christopher Cheadle, Victoria J. South
  • Patent number: 6210879
    Abstract: The present invention relates to a method for diagnosing schizophrenia, said method being based on the detection in vitro of the presence of the allele Ep of the microsatellite HUNTH01 in the gene TH. The invention also relates to the primers used for implementing said method.
    Type: Grant
    Filed: December 22, 1997
    Date of Patent: April 3, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Rolando Meloni, Claudine Laurent, Jacques Mallet
  • Patent number: 6210963
    Abstract: Cell compositions containing mononuclear phagocyte systems cells, and their use in cell therapy, e.g. adoptive immunotherapy, are disclosed.
    Type: Grant
    Filed: April 24, 1996
    Date of Patent: April 3, 2001
    Assignees: Institut National de la Sante et de la Recherche Medicale, Rhone-Poulenc Rorer S.A.
    Inventors: Hedi Haddada, Manuel Lopez, Michel Perricaudet
  • Patent number: 6211234
    Abstract: Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: April 3, 2001
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Peter Charles Astles, Mark Francis Harper, Neil Victor Harris, Iain McFarlane McLay, Roger John Aitchison Walsh, Richard Alan Lewis, Christopher Smith, Barry Porter, Clive McCarthy
  • Patent number: 6207675
    Abstract: The invention concerns pyrrole derivatives of general formula (I) useful for treatment and prevention of diseases in which are involved viruses of the herpes family and/or cytokines in particular TNF&agr;.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: March 27, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jean-Christophe Carry, Serge Mignani, Conception Nemecek
  • Patent number: 6200798
    Abstract: The present invention relates to new viral vectors derived from adenoviruses, their preparation and utilization in gene therapy. It relates particularly to defective recombinant adenoviruses wherein the Iva2 gene at least is inactivated.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: March 13, 2001
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Patrice Yeh, Michel Perricaudet, Cécile Orsini, Emmanuelle Vigne
  • Patent number: 6197980
    Abstract: 4-acetoxy-2&agr;-benzoyloxy-5&bgr;, 20-epoxy-1&bgr;, 7&bgr;, 10&bgr;-trihydroxy-9-oxo-11-taxen-13&agr;-y1(2R,3S)-3-t-butoxycarbonylamino-3-phenyl-2-hydroxypropionate trihydrate obtained by a process of centrifugal partition chromatography.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: March 6, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: André Durand, Alain Gerbaud, Rodolphe Margraff
  • Patent number: 6194582
    Abstract: New taxoids of general formula (I), their preparation, and pharmaceutical compounds containing them. In general formula (I), for example, Ar represents an aryl radical, R represents an alkoxyacetyl radical, R1 represents a benzoyl radical or a radical of formula R2—O—CO— in which R2 represents an optionally substituted alkyl radical, an alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical. The new products of general formula (I) have a remarkable antitumor activity.
    Type: Grant
    Filed: July 31, 1998
    Date of Patent: February 27, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Hervé Bouchard, Jean-Dominique Bourzat, Alain Commercon
  • Patent number: 6194412
    Abstract: The present invention relates to mixtures which can be isolated from grains of Eugenis Jambolana Lamarck, the preparation of such mixtures, the medicaments containing said mixtures or constituents of said mixtures, and the use of these mixtures and constituents for the preparation of a medicament.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: February 27, 2001
    Assignees: Rhone-Poulenc Rorer S.A., Institut Malgache de Recherches
    Inventors: Albert Rakoto Ratsimamanga, Suzanne Rakoto Ratsimamanga, Philippe Rasoanaivo, Jean Leboul, Jean Provost, Daniel Reisdorf
  • Patent number: 6187746
    Abstract: The present invention relates to injectable compositions containing a dalfopristine/quinupristine combination comprising an aqueous solution containing the dalfopristine/quinopristine combination and an additive intended to avoid or reduce the intolerance effects at the site of injection.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: February 13, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Guillaume Conrath, Joël Vacus, Nicholas Paul Barker
  • Patent number: 6187548
    Abstract: The present invention relates to the isolation of a cDNA clone encoding the calcium sensor in human placenta and subsequent Northern blots confirming the mRNA expression also in human parathyroid and kidney tubule cells. Close sequence similarity is demonstrated with the rat Heymann nephritis antigen, a glycoprotein of the kidney tubule brush border with calcium binding ability. Immunohistochemistry substantiates a tissue distribution of the calcium sensor protein similar to that previously described for the Heymann antigen. It is proposed that the identified calcium sensor protein constitutes a universal sensor for recognition of variation in extracellular calcium, and that it plays a key role for calcium regulation via different organ systems. The calcium sensor protein belongs to the LDL-superfamily of glycoproteins, claimed to function primarily as protein receptors, but with functionally important calcium binding capacity.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: February 13, 2001
    Assignee: Rhone-Poulenc Rorer Pharmaceuticals Inc.
    Inventors: Göran Akerström, Claes Juhlin, Lars Rask, Göran Hjälm, Clarence C. Morse, Edward M. Murray, Gregg R. Crumley
  • Patent number: 6180362
    Abstract: Peptides capable of inhibiting the transforming activity of activated p21 proteins, their preparation and compositions containing them are disclosed. Particular regions of the GAP protein have been identified and characterized that are involved in the transduction of activation signals of p21 proteins. Peptides derived from GAP protein but carrying an effector region rendered non-functional have been shown to inhibit the p21 signaling route. The products according to the invention are useful in pharmaceutical compositions to inhibit the transformation activity of ras genes whose transformation proceeds by a functional p21-GAP interaction.
    Type: Grant
    Filed: April 24, 1995
    Date of Patent: January 30, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marc Duchesne, Fabien Schweighoffer, Bruno Tocque
  • Patent number: 6160135
    Abstract: Novel taxoids of general formula (I), the preparation thereof and pharmaceutical compositions containing same, are disclosed. In general formula (I), Z is a hydrogen atom or a radical of general formula (H), wherein R.sub.1 is an optionally substituted benzoyl radical or a radical R.sub.2 --O--CO--, where R.sub.2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, optionally substituted phenyl or heterocyclyl radical; R.sub.3 is an alkyl, alkenyl, alkyl, cycloalkyl, phenyl, naphthyl or aromatic heterocyclic radical; R.sub.4 is a hydroxy radical or an alkoxy, alkenyloxy, optionally substituted alkynyloxy, alkanoyloxy, alkenoyloxy, alkynyloxy, alkoxyacetyl or alkyloxycarbonyloxy radical, or a cycloalkyloxy, cycloalkenyloxy, arylcarbonyloxy or heterocyclylcarbonyloxy radical; and R.sub.5 is an optionally substituted alkoxy radical or a cycloalkyloxy or cycloalkenyloxy radical.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: December 12, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Herve Bouchard, Jean-Dominique Bourzat, Alain Commer.cedilla.on
  • Patent number: 6156545
    Abstract: The present invention relates to a biosynthetic process for preparing cobalamines. More precisely, it relates to a process for amplifying the production of cobalamines and, more specifically, of coenzyme B.sub.12 by means of recombinant DNA techniques and/or by means of adding a novel cobalamine precursor.
    Type: Grant
    Filed: March 2, 1999
    Date of Patent: December 5, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Francis Blanche, Beatrice Cameron, Joel Crouzet, Laurent Debussche, Denis Thibaut, Elisabeth Remy
  • Patent number: 6156789
    Abstract: This invention relates to a method for treating abnormal cell proliferation in the brain by administering a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof: ##STR1## in which R represents a hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical, R.sub.1 represents a benzoyl radical or a radical R.sub.2 --O--CO-- wherein R.sub.2 represents an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclylic radical, and Ar represents an aryl radical.
    Type: Grant
    Filed: March 17, 1998
    Date of Patent: December 5, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marie-Christine Bissery, Alain Renard
  • Patent number: 6150387
    Abstract: This invention relates to the use of heterocyclic carboxamide compounds for preventing or reducing self-administration, by a human or animal patient, of a drug or a substance capable of giving rise to pharmacomania or to overuse. The preferred types of drugs or substances are nicotine, caffeine, benzodiazepines, narcotics, and hallucinogens.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: November 21, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Andrees Bohme, Marie-Christine Dubroeucq, Walter Fratta, Claude Guyon, Assunta Imperato, Franco Manfre
  • Patent number: 6146663
    Abstract: This invention relates to stabilized nanoparticles which may be filtered under sterile conditions, comprising at least one hydrophobic, water-insoluble and non-water-dispersible polymer or copolymer (and optionally an active principle) which is emulsified in an aqueous solution or suspension comprising a phospholipid and a bile salt.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: November 14, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marie-Christine Bissery, Michel Laborie, Joel Vacus, Thierry Verrecchia
  • Patent number: 6143518
    Abstract: Expression plasmids comprising a nucleic acid sequence of interest controlled by a T7 bacteriophage promoter and a stabilizing region comprising all or part of the par region of the RP4 plasmid or a derivative thereof. The invention also concerns the use of said plasmids in the production of recombinant products.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: November 7, 2000
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Beatrice Cameron, Joel Crouzet